Cadila Healthcare on Friday said it has not received any observation from the US health regulator after the inspection of its Ahmedabad manufacturing facility.
The United States Food and Drug Administration inspected the company’s topical manufacturing facility in Ahmedabad during December 16-20, 2019, the drug firm said in a BSE filing. “At the end of the inspection, no observation (483) is issued ,” it added. Shares of Cadila Healthcare gained 1.78 per cent at ₹266.20, on the BSE.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.